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ABSTRACT 
This review gives the information about the Finasteride i.e. 5alpha-reductase inhibitor. Primarily finasteride isused to treat BPH i.e benign 
prostatic hyperplasia and male androgenetic alopecia. Five-alpha reductase inhibitors (5α-RIs) could stimulate male sexual dysfunction due to 
their effects on testosterone and DHT i.e. dihydrotestosterone. Some studies account insignificant or acceptable adverse effects, which decrease 
after a changeable period of time so that they do not require terminating finasteride administration. The 5alpha-reductase inhibitor finasteride 
blocks the conversion of TT to DHT i.e. testosterone to dihydrotestosterone (DHT), the androgen responsible for androgenetic alopecia i.e. male 
pattern hair loss. This paper presents a possible explanation of the Finasteride drug. 
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INTRODUCTION: 
5a-reductase inhibitors were developed around 20 years 
ago. Finasteride was the very specific inhibitor of the human 
type 2 5a-reductase enzyme developed for clinical use.5a-
reductase inhibitors (5a-RIs), finasteride and dutasteride, 
have been approved for treatment of lower urinary tract 
symptoms, because of benign prostatic hyperplasia, with 
marked clinical efficacy. Finasteride is also permitted for 
treatment of hair loss (androgenetic alopecia). Although the 
adverse side effects of these agents are thought to be 
nominal, the extent of adverse effects on sexual function, 
Gynecomastia, depression, and quality of life remains ill-
defined. [1] 
Finasteride is a competitive inhibitor for 5 alpha-reductase 
enzyme, being currently used as a pharmacological 
therapeutic approach of male androgenic alopecia and 
benign prostatic hyperplasia. Administration of Finasteride 
is able to induce behavioral changes to animals, while in 
humans depressive symptoms were relatively frequently 
reported. For this reason, it was suggested for Finasteride to 
be carefully administered to patients presenting a history or 
a high risk to developing depression. [2]. 
Finasteride (FINA) is chemically N- (1,1-dimethylethyl) –3-
oxo-4-aza-5-androst-1-ene- 17- carboxamide. Finasteride 
(FINA) is an specific inhibitor of steroid 5α-reductase; blocks 
conversion of testosterone by type II 5α-reductase to 5α 
dihydrotestosterone (DHT). It is used for the treatment of 
the symptomatic benign prostatic hyperplasia and male 
pattern hair loss (androgenetic alopecia) in men. It is official 
in Indian Pharmacopoeia (IP), BP and USP. [3] 
Finasteride Structure  
 
HISTORY OF FINASTERIDE: 
Under the code name MK-906 finasteride was developed by 
Merck. Finasteride (5 mg) was approved by the U.S in 1992. 
Food and Drug Administration (FDA) for treatment of BPH 
(Benign Prostatic Hyperplasia), which is marketed under the 
brand name Proscar by Merk. Merck was successful in 
obtaining FDA approval for a second indication of finasteride 
(1 mg) for treatment of male pattern hair loss in 1997, which 
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was marketed under the brand name Propecia. It was the 
first 5α-reductase inhibitor to be introduced and was 
followed by dutasteride in 2001.The first study of finasteride 
in the treatment of hirsutism in women was published in 
1994. [4,5] 
BRAND NAME OF FINASTERIDE: 
Proscar and Propecia are trade names for the same drug, 
finasteride. The variation in between these two is in dosage 
and indication. Proscar is 5 mg of finasteride and is indicated 
for the treatment of BPH i.e. (Benign Prostate Hyperplasia). 
Propecia is 1 mg of finasteride and is indicated for the 
treatment of male pattern baldness. [6] 
GENERAL DESCRIPTION:  
Chemically finasteride is 17β-(N-tert-butylcarbamoyl)-4- 
aza-5α-androst-1-en-3-one.It is white in colour and in 
crystalline powder form as well as amorphous nature. The 
molecular weight of finasteride is 372.6g/ml and molecular 
formula of this finasteride is C23H36N2O2. finasteride is 
competitive inhibitor of enzyme 5α- reductase which 
converts testosterone responsible for androgen action in 
tissues together with prostate gland and hair follicles. 
Finasteride is anti-androgenic drug and also found 
successfully in male baldness. It is effective orally, 
metabolized in liver and excreted in urine faeces. [7] 
Finasteride is used in benign prostatic hyperplasia (BPH) in 
small doses and in prostate cancer in large doses. In addition, 
it is registered in several countries for male pattern-
baldness. The therapeutic significance of finasteride has 
necessitated the development of analytical methods for its 
determination in dosage forms in compliance with good 
manufacturing standards. [8] 
FINASTERIDE’S MECHANISM OF ACTION: 
Finasteride is a competitive 5 alpha-reductase inhibitor for 
type II and III isoenzymes that preventing the conversion of 
testosterone to dihydrotestosterone. As a result, the serum 
level of dihydrotestosterone decreases after Finasteride 
administration with about 65–70%. Finasteride doesn’t 
inhibit the type I of 5 alpha-reductase isoenzyme due to this 
fact the partial inhibition of dihydrotestosterone synthesis is 
occur. Finasteride contributes to reduction of GABAA activity 
(dihydrotestosterone helps activation of GABAA receptors) 
by decreasing the level of dihydrotestosterone, which has 
been involved in depression, anxiety and sexual 
dysfunctions. Yet, Finasteride decreases androgen activity in 
the scalp and prostate. [2] 
Mechanism of action of finasteride which leads to reduced 
levels of DHT when the drug is administered orally, which 
shows a balanced approach to the treatment of men with 
AGA. Since it is a systemic medication, finasteride is 
delivered to the intact scalp, including the affected areas. The 
clinical studies established awareness to finasteride 
treatment across a broad range of men with AGA, those with 
mild to moderate degrees of hair loss in the vertex and 
anterior mid-scalp areas. No major clinical or laboratory 
adverse effects have been observed with finasteride 
administration that prohibit its long-term use by men. 
Moreover, finasteride is not a new drug, and worldwide 
experience with a higher dose of finasteride over many years 
in the treatment of men with BPH confirms the long-term 
safety of the compound. The value of Finasteride in the 
treatment of men with androgen-dependent disorders, 
including AGA, has prompted the development of other 
inhibitors of 5a-reductase, as well as increasing research in 
modulators of androgen action, for potential use in treating 
men with these disorders.[9] 
The mechanism of action of finasteride in humans is based 
on its preferential inhibition of the Type II isozyme. In vitro 
binding studies that examined finasteride’s ability to inhibit 
either isozyme of 5á-reductase documented a 100-fold 
selectivity for the human Type II over the Type I isozyme. 
Based on the tissue-specific expression of Type II 5á-
reductase in humans, currently approved clinical uses for 
finasteride target the diminution of DHT levels and the 
concomitant decrease in activity of DHT at the androgen 
receptor in the prostate and the scalp of men. In contrast to 
the selective inhibition of the Type II isozyme by finasteride 
in humans, both isozymes of the 5á-reductase enzyme in the 
rodent demonstrate comparable inhibition following 
finasteride exposure.[10] 
PHARMACODYNAMICS AND PHARMACOKINETICS: 
In humans, primarily Type I 5á-reductase is found in the 
sebaceous glands of most regions of skin including scalp, and 
in liver, muscle, and brain with low levels also present in 
prostate that may boost in prostate cancer. Approximately 
one-third of circulating DHT is due to the type I 5á-reductase. 
The Type II 5á-reductase isozyme is found in prostate, 
seminal vesicle, epididymis, and hair follicles as well as in 
liver and is responsible for the remaining two-thirds of 
circulating DHT. Because of this profile of tissue specific 
expression and the specificity of finasteride inhibition in 
humans, few adverse reactions are observed in other organ 
systems. Finasteride has no affinity for the androgen 
receptor and exhibits no known androgenic, anti-androgenic, 
estrogenic, anti-estrogenic, or progesterone-like activity . 
The rodent 5á-reductase isozymes also differ in the 
mechanism by which finasteride inhibits their enzymatic 
activity. Finasteride acts as a classical competitive inhibitor 
of the rat Type I enzyme and time-dependently dissociates 
from this isozyme, whereas it binds and irreversibly modifies 
rat Type II 5á-reductase following the formation of a high 
affinity complex. This mechanistic difference in finasteride 
binding between rat isozymes results in a 10-fold difference 
in Ki values Little is known regarding the recovery of the 5á-
reductase enzymes and the subsequent restoration of 5á-
reduced steroid metabolite levels following the cessation of 
finasteride treatment in rodents. Based on the competitive 
vs. irreversible inhibition of the two 5á-reductase enzymes, it 
is feasible that the rat Type I enzyme would recover more 
quickly than the Type II enzyme. This difference may have 
important implications in the rodent, given that Type I is 
predominantly localized in the CNS and Type II 5á-reductase 
is largely in the periphery. [10] 
PHARMACOKINETICS: 
The mean oral bioavailability of finasteride is approximately 
65%.The absorption of finasteride is not affected by 
food. With 1 mg/day finasteride at steady-state mean peak 
concentrations of finasteride were 9.2 ng/mL (25 nmol/L).. 
The volume of distribution of finasteride is 76 L/kg. Its 
plasma protein binding is 90%.The drug has been found to 
cross the blood–brain barrier, whereas levels in semen were 
found to be untraceable. Finasteride is widely metabolized in 
the liver, It has two major metabolites, which are the tert-
butyl side chain mono-hydroxylated and mono-carboxylic 
acid metabolites. These metabolites show approximately 
20% of the inhibitory activity of finasteride on 5α-
reductase.Hence, the metabolites of finasteride are not 
principally active. The drug has a terminal half-life of 5-
6 hours in adult men (18–60 years of age) and a terminal 
half-life of 8 hours or more in elderly men (more than 
70 years of age).It is eliminated as its metabolites 57% in 
the feces and 40% in the urine.[11,12] 
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PHARMACOLOGICAL PROFILE OF FINASTERIDE: 
Finasteride is a partial inhibitor (only type II) of 5α-
reductase enzyme, which converts intracellular testosterone 
to dihydrotestosterone. Finasteride absorption is not 
affected by food, presenting a bioavailability around 65%. 
The maximum plasmatic concentration is reached about 1  to 
2  hours after administration, ranging between 4.9  - 13.7 
ng/mL for 1 mg/day, and between 27 - 49 ng/mL for 5 
mg/day. After successive doses, there is a slow accumulation 
phase for Finasteride, with 90% of the circulating drug 
bound to plasma proteins. 
Finasteride crosses the blood-brain barrier, a property that 
explains many Finasteride side effects such as mental and 
sexual impairments. It is extensively metabolized by the 
liver, especially through cytochrome P450 3A4 enzyme 
subfamily. The corresponding metabolites possess no more 
than 20% inhibitory activity for 5α-reductase comparable to 
Finasteride action. Oral administration of Finasteride leads 
to its excretion in urine as metabolites (about 39%) and 
through feces (57%, in part unmetabolized). The mean 
terminal half-life of finasteride in men between 45  - 60 years 
is approximately 6 hours, though longer in men over 70 
years (about 8 hours). [13]  
FINASTERIDE: USE IN MALE PATTERN HAIR LOSS 
The 5alpha-reductase inhibitor finasteride blocks the 
conversion of TT to DHT i.e. testosterone to 
dihydrotestosterone (DHT), the androgen accountable for 
male pattern hair loss (androgenetic alopecia) in genetically 
predisposed men. In 1879 the  results of phase III clinical 
studies in men have shown that oral finasteride 1 mg/day 
prevents further hair loss promotes hair growth and in a 
significant proportion of men with male pattern hair loss. 
Data suggests that the improvement in hair count reported 
after 1 year is maintained during 2 years' treatment. In men 
with vertex hair loss, global photographs showed 
enhancement in hair growth in 48% of finasteride recipients 
at 1 year and in 66% at 2 years compared with 7% of placebo 
recipients at each time point. Furthermore, hair counts in 
these men showed that 83% of finasteride versus 28% of 
placebo recipients had no further hair loss compared with 
baseline after 2 years. The clinical efficiency of oral 
finasteride has not yet been compared with that of topical 
minoxidil, the only other drug used clinically in patients with 
male pattern hair loss. Well tolerated Therapeutic dosages of 
finasteride. In phase III studies,7.7% of patients getting 
finasteride 1 mg/day compared with 7.0% of those getting 
placebo reported treatment-related adverse events. The 
overall frequency of sexual function disorders, comprising 
decreased libido, ejaculation disorder and erectile 
dysfunction, was extensively greater in finasteride than 
placebo recipients. All sexual adverse actions were reversed 
on discontinuation of the therapy and many resolved in 
patients who continued therapy. No other drug-related 
events were reported with an occurrence > or =1% in 
patients receiving finasteride. Most events were of placid to 
moderate severity. Oral finasteride is contraindicated in 
pregnant women because of the risk of hypospadias in male 
fetuses. [14] 
THE EFFECT OF FINASTERIDE IN MEN WITH 
BENIGN PROSTATIC HYPERPLASIA 
BPH i.e. Benign prostatic hyperplasia is a advanced, 
androgen-dependent disease resulting in enlargement of the 
prostate gland and urinary obstruction. The treatment of 
BPH i.e. benign prostatic hyperplasia with 5mg of finasteride 
per day that results in a significant decrease in symptoms of 
obstruction and enhance in the urinary flow and decrease in 
prostatic level but with slightly increased risk of sexual 
dysfunction. [15] A 5-mg dose of finasteride is permitted for 
treatment of symptomatic BPH (Benign prostatic 
hyperplasia), which reduces prostate level by 19–27% . 
Finasteride has been shown to be most efficient in men with 
enlarged prostates and the most rigorous symptoms. 
Finasteride is also permitted for the treatment of male-
pattern hair loss (androgenetic alopecia) and vertex 
baldness, and is generally given at a lower dose of 1 mg. [9] 
FINASTERIDE-ANDROGEN-DEPENDENT HAIR 
DISORDERS: 
Finasteride is widely used for the treatment of androgen-
dependent hair disorders such as androgenetic alopecia. 
Finasteride is a selective 5 alpha reductase inhibitor and is 
administered orally in a dose of 1 mg once daily for 
androgenetic alopecia. The oral bioavailability is 65%. It is 
not related to food intake. The average peak plasma 
concentration is found to be 9.2 ng/ml. The terminal half-life 
of finasteride is approximately five to six hours in men 
between 18 and 60 years of age and eight hours in men older 
than 70 years of age. It is broadly metabolized in the liver by 
cytochrome-P450; 3A4 enzyme subfamily and excreted in 
urine and feces. Finasteride has been tried in several doses 
ranging from 0.2 mg to 5 mg but 1 mg per day is the optimal 
dose for the treatment of men with male pattern hair loss. 
There is no difference in efficacy between doses of 1 mg and 
5 mg. Long-term daily finasteride is advocated and leads to 
sustained improvement. [16] 
HAIRLOSS: 
Hair loss not only constitutes one of the most commonly 
encountered problems for dermatologists, it inflicts a 
reflective negative impact on one’s quality of life. Advanced 
patterned hair loss (PHL), particularly at an early age is 
frequently a source of depression in young individuals. 
Androgenetic alopecia (AGA) affects both genders in a 
distinctive pattern of hair loss from the scalp (MPHL i.e. male 
pattern hair loss for male PHL and FPHL i.e. Female pattern 
hair loss for or female PHL). Mid-frontal hair loss affects 
closely two thirds of women and three quarters of men over 
the age of 80 years. Loss of hair from the vertex is typical of 
MPHL( male pattern hair loss ), encountered in number of 
affected men. The trademark of the condition is advanced 
and gradual shrinking of hair follicles (HFs), accompanied by 
progressive decrease in the duration of anagen and 
reduction of anagen to telogen ratio. Additionally in AGA 
(Androgenetic alopecia) , there is a time lag between the end 
of the telogen phase and the beginning of the new anagen 
phase and a resting phase called kenogen during which the 
hair follicle remains bare. The follicular miniaturization in 
AGA is an asynchronous phenomenon even within a follicular 
unit (FU); with affection of secondary follicles occurring in 
the initial phase and the primary follicles in the last. In 
contrast, the miniaturization activity is synchronous in 
alopecia areata (AA).Finasteride (FIN), the only United States 
Federal Drug Administration (FDA) approved oral agent for 
MPHL is a specific inhibitor of 5AR, type II isoform. Minoxidil 
(MNX), the other FDA approved topical agent (for MPHL as 
well as FPHL) apparently acts by increasing follicular 
vascularity (as a potassium channel opener), prolonging 
anagen and shortening telogen, and also by converting  
partially miniaturized (intermediate) hair follicles to 
terminal hair. Hair transplantation, of course remains one of 
the best and sometimes the only therapeutic option in 
advanced AGA. [17] 
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USE IN FEMALE ALOPECIA: 
Currently minoxidil is considered the first-line therapy for 
female pattern alopecia; however, finasteride and 
dutasteride are becoming more frequently used. The most 
significant adverse effect of 5ARIs in women who are or may 
become pregnant is the risk of birth defects in the male fetus. 
5ARI exposure to pregnant women has been shown to 
increase the risk of abnormal male external genital 
development including hypospadias. Due to this risk, 5ARIs 
are considered contraindicated in pregnancy with some 
authors advocating testing to rule out pregnancy before 
starting 5ARIs and concomitant reliable contraception use in 
nonpregnant women with childbearing potential.5-alpha 
reductase inhibitors, such as finasteride and dutasteride, are 
becoming more commonly prescribed for women with hair 
loss. The limited number of studies indicates that 5ARIs are 
well-tolerated initially with no increased risk of malignancy 
or severe side effects. However, headache, gastrointestinal 
discomfort, and decreased libido are the most common side 
effects reported. Future long-term studies would be helpful 
to fully. assess adverse events with chronic use.[18]The 
mechanisms by which finasteride may arrest or reverse hair 
loss in women remain unknown. The largest controlled trial 
to date did not demonstrate significant stabilization or 
improvement in hair loss. There is little evidence to support 
any agent as second-line treatment for female hair loss; 
however, data from uncontrolled studies and case reports 
suggest that finasteride may be effective in an as-yet 
unidentified subgroup of patients with FPHL(Female pattern 
hair loss).  Finasteride should therefore be reserved for 
treatment of FPHL not responding to a 12-month trial of 
topical minoxidil. The MPHL finasteride regimen of 1 mg 
orally daily is suggested for treatment of FPHL, although 
some success has been noted with doses of 2.5 and 5 mg 
daily. Due to its known teratogenicity, finasteride treatment 
should be restricted to nonpregnant women who adhere to 
reliable contraception if they are of childbearing 
potential.[19] 
ROLE OF ANDROGENS IN PATTERN HAIRLOSS AND 
SEXUAL FUNCTION: 
Pattern hair loss i.e. PHL in male is androgenic in aetiology. 
Antiandrogens like finasteride are therefore usable in the 
management of the condition. Androgens, particularly 
testosterone increases the libido. Any drug which hinders 
with the action of androgens is therefore assumed, by the lay 
person, to induce impotence. However, the precise role of 
androgen in penile erection needs to be fully elucidated. 
Even an individual with low testosterone levels can achieve 
erection. In addition to androgens, visible, olfactory, tactile, 
auditive, and imaginative stimuli causation the libido. The 
penile erection is mainly under the control of 
parasympathetic nervous system. Ejaculation and 
detumescence require an intact sympathetic system. The 
androgens testosterone and dihydrotestosterone (DHT) have 
somewhat different actions. The enzyme, 5α-reductase 
converts testosterone to DHT. It exists in two isoenzyme 
forms. While type I is predominant in liver, type II is 
predominant in prostate, seminal vesicles, epididymis, hair 
follicles, and liver.Within the hair follicle too, the two types 
have a different distribution. Type I 5AR, is generally present 
in the sebaceous gland, while type II 5AR is present on the 
outer root sheath of the hair follicles and dermal papillae. At 
all these sites, the testosterone is converted to DHT. 
Although the type II 5AR enzyme has a more significant role 
in pattern hairloss (and therefore mechanism of action of 
finasteride), the predominant enzyme in scalp skin is type I 
,largely because of localization to the sebaceous glands, 
which are large and plenty in scalp. We know that the 
finasteride is a specific and competitive inhibitor of Type II 
5-AR, and has therefore a selective action on hair follicles. 
Scalp skin DHT levels fall by more than 60% after 
administration of finasteride, thereby suggesting that a 
significant amount of DHT found in scalp skin is derived from 
both local DHT production and circulating DHT. Thus, the 
effect of finasteride on scalp DHT is likely because of its 
effect on both local follicular DHT levels as well as serum 
DHT levels. This explains why relatively small dose of 
finasteride may be adequate therapeutically.[20,21] 
SEXUAL ADVERSE EFECTS: 
Sexual side effects in men who have taken fInasteride (1mg, 
5mg) and dutasteride (0.5mg) are well documented and 
include decreased libido, erectile dysfunction, and 
ejaculatory dysfunction.  
Randomized clinical trials have demonstrated increased 
incidences of these sexual side effects.[22] 
In most of the men who improved persistent sexual side 
effects (near about ≥3 months) despite the discontinuation of 
finasteride, the sexual dysfunction continued for numerous 
months or years. Although various rat studies have shown 
harmful changes to erectile function caused by 5 alpha 
reductase inhibitors (finasteride), the persistent nature of 
these changes is an area of active research. Prescribers of 
finasteride and men contemplating its use should be made 
aware of the potential adverse medication effects.[23] 
MALE BREAST CANCER DURING FINASTERIDE 
THERAPY: 
Male breast cancer is an uncommon disease, with an 
estimated incidence of one case per 100 000 man-years . 
Relative estrogen excess or lack of androgen are associated 
with an increased risk of breast cancer in both women  and 
men .An example of increased rates of male breast cancer 
associated with increased estrogen-to-testosterone ratios 
can be seen in men with Klinefelter’s syndrome, who are 50 
times more likely to develop breast cancer than their normal 
counter parts. Sometimes, this ratio affected by ﬁnasteride 
(Proscar), which has been widely marketed and used to treat 
benign prostate hyperplasia (BPH). Proscar shrinks 
androgen-dependent prostate tissue by inhibiting steroid 
5alpha-reductase, an enzyme that converts testosterone to 
dihydrotestosterone (DHT). However, inhibition of DHT 
production alters the estrogen-to androgen ratio and may 
also increase the risk of gynecomastia and male breast 
cancer. Reports to the U.S. FDA from June 1992 through 
February 1995 pretending that gynecomastia had been 
observed in 214 men receiving Proscar therapy.  
Two of these men were afterwards found to have invasive 
ductal breast carcinoma . There was also a higher incidence 
of gynecomastia in men participating in the Prostate Cancer 
Prevention Trial. The rate of gynecomastia was 426 (4.5%) 
of 9423 subjects randomly allotted to the Proscar arm 
compared with 261 (2.8%) of 9457 subjects randomly 
allotted to the placebo arm. There was one case of breast 
cancer in each and every arm of the trial. Evidence of the 
organization of Proscar with male breast cancer comes from 
the Medical Therapy of Prostatic Symptoms (MTOPS) study, 
a National Institutes of Health (NIH)-sponsored study of 
about 3047 men that compared Proscar, doxazosin, and the 
combination for the treatment of BPH . Men were randomly 
assigned to one of four treatment arms: Proscar and 
doxazosin (n  786), Proscar (n  768), doxazosin (n  756), and 
placebo (n  737). Four cases of breast cancer were reported. 
According to a letter from the NIH to the MTOPS principal 
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investigators, one man in the Proscar/doxazosin group and 
three in the Proscar-alone group developed male breast 
cancer. The rate of breast cancer in this trial for men taking 
Proscar either alone or with doxazosin was therefore 4 in 
1554, or nearly 200 times that of the general population. One 
of us (S. C. Lee) was patient No. 14–214 who participated in 
the MTOPS trial from 1997 through 2002 and wasrandomly 
assigned to receive 5 mg of Proscar daily. This patient was a 
previously healthy 69-year-old man with no family history of 
cancer who developed lymph node–positive estrogen and 
progesterone receptor–positive breast cancer (tumor–node– 
metastasis [TNM] staging T1cN1M0). He was subsequently 
treated with modiﬁed radical mastectomy with axillary 
lymph node dissection, chemotherapy, and tamoxifen. He 
was one of the four breast cancer cases mentioned in the 
letter from the NIH to the MTOPS. As this patient and his 
physician, we strongly suggested that the FDA require that 
data about the possible association between male breast 
cancer and Proscar be clearly stated in the manufacturer’s 
patient information leaﬂet for prescriptions and in its 
advertisements. Proscar has been well accepted to improve 
quality of life in men suffering from BPH i.e. Benign prostate 
hyperplasia. Patients and their physicians need to be better 
informed about this potential life-threatening risk. Men who 
take Proscar need to be aware of any changes in their breasts 
and report these changes immediately to their 
physicians.[24] 
CONTRAINDICATIONS: 
Finasteride may cause birth defects in a male fetus if a 
pregnant woman takes finasteride or is exposed to 
finasteride pill fragments. It is classified in the FDA 
pregnancy category X. Finasteride stimulate equivocal 
genitalia in male fetuses when granted to pregnant rhesus 
monkeys, whereas no abnormalities are observed in female 
fetuses. There is a single case report of accidental finasteride 
exposure during pregnancy, although in a female infant. 
[25,26] 
CONCLUSIONS 
Finasteride is 5alpha reductase inhibitor. Finasteride mainly 
used in the male pattern hair loss i.e. MPHL as well as in BPH 
i.e.  benign prostate hyperplasia but  not approved 
for prevention of prostate cancer..Mechanism of finasteride is 
depend on the level of testosterone and DHT i.e. 
dihydrotestosterone, finasteride blocks the conversion of 
testosterone to dihydrotestosterone. Overdose of finasteride 
may causes harm to the patient and finasteride 
contraindicated in some cases like in pregnancy etc. 
Finasteride administered during pregnancy causes birth 
defect. Finasteride have some sexual adverse effect which 
may lead to severe disorders. 
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